Trial Profile
A Phase IIa Trial of Brilaroxazine (RP 5063) in Patients with Idiopathic-Pulmonary-Fibrosis (IPF)
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 06 Jan 2023
Price :
$35
*
At a glance
- Drugs Brilaroxazine (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Reviva Pharmaceuticals
- 04 Jan 2023 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in 2023.
- 27 Jul 2022 According to a Reviva Pharmaceuticals media release, the company is planning to initiate this study in Q4 2022.
- 15 Nov 2021 According to a Reviva Pharmaceuticals media release, the company is planning regulatory to the U.S. Food and Drug Administration (FDA) by the end of Q1 2022 to initiate this study.